Trial Profile

A phase 2 study evaluating 2-Deoxy-D-glucose (2-DG)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 2-deoxy-D-glucose (Primary)
Indications Nose disorders; Rhinovirus infections
Focus Therapeutic Use

Most Recent Events

10 Apr 2024 According to a G.ST Antivirals media release, Planned number of volunteers to be enrolled in this trial is 128.
09 Apr 2024 According to a G.ST Antivirals media release, company announced the appointment of Ronald Bruce Turner, MD, as new Chief Medical Officer (CMO).
09 Apr 2024 According to a G.ST Antivirals media release, first subject was dosed on April 2nd, 2024

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com